These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35129063)

  • 1. Partial treatment response to capmatinib in
    Lefler DS; Tierno MB; Bashir B
    Cancer Biol Ther; 2022 Dec; 23(1):112-116. PubMed ID: 35129063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
    Turpin A; Descarpentries C; Grégoire V; Farchi O; Cortot AB; Jamme P
    Oncologist; 2023 Jan; 28(1):80-83. PubMed ID: 36434677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a
    Conci N; Marchiori V; Federico AD; Giglio A; Sperandi F; Melotti B; Gelsomino F
    Per Med; 2024; 21(4):205-209. PubMed ID: 38958204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
    Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Met targeted therapy of cholangiocarcinoma.
    Socoteanu MP; Mott F; Alpini G; Frankel AE
    World J Gastroenterol; 2008 May; 14(19):2990-4. PubMed ID: 18494048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
    Ramesh S; Cifci A; Javeri S; Minne RL; Longhurst CA; Nickel KP; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1379-1390. PubMed ID: 37979706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
    Merath K; Tiwari A; Parikh AA; Pawlik TM
    Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infigratinib for cholangiocarcinoma.
    Sadeghi S
    Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 14. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
    Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
    Schuler M; Berardi R; Lim WT; de Jonge M; Bauer TM; Azaro A; Gottfried M; Han JY; Lee DH; Wollner M; Hong DS; Vogel A; Delmonte A; Akimov M; Ghebremariam S; Cui X; Nwana N; Giovannini M; Kim TM
    Ann Oncol; 2020 Jun; 31(6):789-797. PubMed ID: 32240796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-MET in intrahepatic cholangiocarcinoma: High-Frequency amplification predicts protein expression and a unique molecular subtype.
    Pu XH; Yue S; Wu HY; Yang J; Fan XS; Fu Y; Ye Q; Chen J
    Pathol Res Pract; 2020 Apr; 216(4):152857. PubMed ID: 32089411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capmatinib: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(11):1125-1131. PubMed ID: 32557339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
    Dagogo-Jack I; Moonsamy P; Gainor JF; Lennerz JK; Piotrowska Z; Lin JJ; Lennes IT; Sequist LV; Shaw AT; Goodwin K; Stevens SE; Do A; Digumarthy SR; Price K; Muzikansky A; Hata AN; Heist RS
    J Thorac Oncol; 2021 May; 16(5):850-859. PubMed ID: 33545388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib.
    Yu Y; Liu Q; Li W; Qu Y; Zhang Y; Liu T
    Oncologist; 2020 Dec; 25(12):1005-1008. PubMed ID: 32897609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.